Last viewed: PHAT


Prices are updated after-hours



nasdaq:PHAT Phathom Pharmaceuticals, Inc.

PHAT | $19.27 | twitter stocktwits trandingview |
Health Technology

(0.0% 1d) (-11.7% 1m) (-59.1% 1y) (0.0% 2d) (1.1% 3d) (5.9% 7d) (39.0% volume)
http://www.phathompharma.com
Sec Filling | Patents | 25 employees

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. It focuses on its vonoprazan product, an oral small molecule potassium-competitive acid blocker. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

add to today's watch list email alert is off




gastrointestinal   treatment  

Press-releases


Phathom Pharmaceuticals to Participate in Two Upcoming Investor Healthcare Conferences
Published: 2021-11-12 (Crawled : 22:00) - globenewswire.com
PHAT | $19.27 | twitter stocktwits trandingview |
Health Technology

conference
Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates
Published: 2021-11-08 (Crawled : 13:15) - globenewswire.com
PHAT | $19.27 | twitter stocktwits trandingview |
Health Technology
| | O: 2.59% H: 0.0% C: -2.96%

results
Phathom Pharmaceuticals Withdraws Public Offering
Published: 2021-10-28 (Crawled : 04:00) - globenewswire.com
PHAT | $19.27 | twitter stocktwits trandingview |
Health Technology
| | O: 8.84% H: 1.37% C: -10.06%

offering
Phathom Pharmaceuticals Withdraws Public Offering - Oct 28, 2021
Published: 2021-10-28 (Crawled : 09:00) - biospace.com/
PHAT | $19.27 | twitter stocktwits trandingview |
Health Technology
| | O: 8.84% H: 1.37% C: -10.06%

offering
Phathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific Meeting
Published: 2021-10-24 (Crawled : 20:20) - globenewswire.com
PHAT | $19.27 | twitter stocktwits trandingview |
Health Technology
| | O: -0.03% H: 4.45% C: 3.36%


Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial
Published: 2021-10-18 (Crawled : 19:00) - biospace.com/
PHAT | $19.27 | twitter stocktwits trandingview |
Health Technology
| | O: 2.92% H: 0.0% C: -18.53%

positive results topline phase 3 trial
Phathom Pharmaceuticals Announces Results from VONO-103, a Phase 1 Study Evaluating Gastric Acid Inhibition of Vonoprazan and Lansoprazole (PREVACID®)
Published: 2021-09-27 (Crawled : 13:00) - biospace.com/
PHAT | $19.27 | twitter stocktwits trandingview |
Health Technology
| | O: 1.13% H: 4.5% C: 2.11%

phase 1 results
Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital
Published: 2021-09-20 (Crawled : 23:00) - biospace.com/
HTGC | $16.6 | twitter stocktwits trandingview |
Finance
| | O: -1.37% H: 1.03% C: -0.3%
PHAT | $19.27 | twitter stocktwits trandingview |
Health Technology
| | O: -2.41% H: 2.53% C: 0.03%


Phathom Pharmaceuticals to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
Published: 2021-08-31 (Crawled : 12:00) - globenewswire.com
MS | News 0 d | $102.77 | twitter stocktwits trandingview |
Finance
| | O: 0.17% H: 0.42% C: 0.15%
PHAT | $19.27 | twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 3.48% C: 2.92%

conference
Phathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory Milestones
Published: 2021-08-10 (Crawled : 13:00) - biospace.com/
PHAT | $19.27 | twitter stocktwits trandingview |
Health Technology
| | O: -0.09% H: 8.84% C: 2.97%

results
See all


Last 15 days Sec forms
File Id Form Date Direction Code Amount Transacted Owned Amount


Your Today's Watch List
Sign in to create a watchlist
Today's Insiders Buying

Yesterday's Insiders Buying